AMT-116(Multitude Therapeutics)

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameAMT-116(Multitude Therapeutics)
Drug Alias NameAMT-116AMT-116-ADC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD44 antigen modulators
TargetsCD44 antigen
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaAmerican Samoa +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMultitude Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMultitude Therapeutics Inc
Inactive CompaniesPuzhong Discovery Medical Technology (Shanghai) Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A